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Abstract: Patients with atopic dermatitis have genetically determined risk factors that affect the barrier function
of the skin and immune responses that interact with environmental factors. Clinically, this results in an intense-
ly pruriginous and inflamed skin that allows the penetration of irritants and allergens and predisposes patients
to colonization and infection by microorganisms. Among the various etiological factors responsible for the
increased prevalence of atopic diseases over the past few decades, the role of vitamin D has been emphasized.
As the pathogenesis of AD involves a complex interplay of epidermal barrier dysfunction and dysregulated
immune response, and vitamin D is involved in both processes, it is reasonable to expect that vitamin D’s status
could be associated with atopic dermatitis’ risk or severity. Such association is suggested by epidemiological and
experimental data. In this review, we will discuss the evidence for and against this controversial relationship,
emphasizing the possible etiopathogenic mechanisms involved. 
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Resumo: Pacientes com dermatite atópica têm fatores de risco geneticamente determinados que afetam a função
de barreira da pele e as respostas imunes, as quais interagem com fatores ambientais. Clinicamente, isso resulta
em uma pele intensamente pruriginosa, inflamada, que permite a penetração de irritantes e alérgenos e predis-
põe os pacientes à colonização e à infecção por micro-organismos. Dentre os diversos fatores etiológicos respon-
sáveis pelo aumento da prevalência de doenças atópicas nas últimas décadas, o papel da vitamina D tem ganha-
do destaque. Uma vez que a patogênese da dermatite envolve uma interação complexa da disfunção da barrei-
ra epidérmica e desregulação da resposta imune - e a vitamina D está envolvida em ambos os processos-, é razoá-
vel esperar que a vitamina D esteja associada ao risco ou à gravidade da dermatite atópica. Tal associação é suge-
rida por dados epidemiológicos e experimentais. Nessa revisão, serão abordadas as evidências favoráveis e con-
trárias a essa polêmica relação, enfatizando os possíveis mecanismos etiopatogênicos envolvidos.
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INTRODUCTION
Atopic dermatitis (AD), a common chronic
inflammatory dermatosis, is clinically distinguished by
pruritus, eczematous plaques and a defective epidermal
barrier. Considered the earliest manifestation of atopy, it
affects preferably children, the majority of which evolve
with remission in adulthood. Nevertheless, the disease
may persist in more than 10% of these patients until
adolescence or adulthood.1-5 Global evidences reflect a
marked increase in prevalence, which has tripled
since 1960. In the United States, the current prevalence
rates range from 10% to 20% in children and 1 to 3%
in adults.6 There is little data on the prevalence of this
disease in Brazil.
New discoveries about genetics and patho-
physiology of AD point to an important role of struc-
tural abnormalities in the epidermis, as well as
changes in the immune system. Environmental factors
and other unidentified aspects may influence the
expression of the disease. The etiopathogenesis of AD
is therefore complex and not yet fully elucidated.5
Vitamin D - classically associated to bone
metabolism and calcium homeostasis - was also iden-
tified as a steroid hormone, and several studies now
emphasize its action on extra skeletal health. Research
linking vitamin D deficiency to an increased risk of
malignancies (especially colorectal), atopic diseases,
autoimmune, infectious and, cardiovascular disor-
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ders, hypertension, metabolic syndrome, neuropsy-
chiatric symptoms and mortality, is noteworthy.7
Hypovitaminosis D is increasingly found in
developing countries. The prevalence of this condition
varies widely between regions, reaching alarming
rates of 30-90%, depending on the cutoff point used.
The reference values to stratify between normal,
insufficient and deficient are controversial and far
from being settled.8 It is estimated that 3 out of 4
Americans and 1 billion people worldwide have vita-
min D insufficiency.9,10
For this review, a PubMed search was per-
formed using the keywords “atopic dermatitis” and
“vitamin D” in addition to “hypovitaminosis D”. The
search was restricted to articles published in English,
with no date limitation. Depending on the content of
abstracts, manuscripts of interest were selected and
included in this review. References of these manu-
scripts were also evaluated in search for relevant
papers. Finally, reviews and publications about this
theme, found in the digital library of the authors, were
also used.
ATOPIC DERMATITIS
AD is a chronic inflammatory disease highly
itchy that often manifests itself during infancy or child-
hood and may persist or begin in adulthood. It can
arise as the first clinical manifestation of childhood’s
atopic diseases. An “atopic march” occurs early in chil-
dren with AD: more than 50% develop asthma and / or
allergies, usually around the age of 3.11 Because of its
chronic and pruritic nature, AD may have greater
impact on the quality of life than asthma, diabetes, cys-
tic fibrosis and enuresis.6,12-14 Because of its chronic itch-
ing and pain, it may cause depressive symptoms, social
isolation and self-perception disorders.15
DA diagnosis is clinical, through established
criteria defined by Hanifin & Rajka (1980),16 which are
classified in major and minor. To achieve the diagno-
sis, 3 criteria of each category are necessary (Chart 1).
ETIOPATHOGENESIS
AD was, for a long time, considered a dysfunc-
tion of keratinocytes. However, over the past two
decades, with advances in the understanding of its
pathogenesis, it has also become regarded as an
immune dysregulation disorder. New concepts have
emerged, demonstrating immunological and inflam-
matory dysfunctions, besides the importance of envi-
ronmental factors.4,17,18
Although about 70% of AD patients have a fam-
ily history of atopy, such as asthma and allergic rhinos-
inusitis, its prevalence varies between countries and
even in regions within the same country. Studies indi-
cate a higher incidence and prevalence in westernized
and developed countries. Thus, environmental factors
- including sun exposure, hygienic and dietary habits -
exert a crucial role in the expression of atopic manifes-
tations. It is possible that early exposure to microor-
ganisms, common in developing countries, contributes
to the immune system maturation, reducing the inci-
dence of AD. It is believed, though, that the contact
with microorganisms by fecal-oral route has greater
protective effect than via respiratory route. 
Patients with AD, due to their impaired immu-
nity, have a unique predisposition for colonization and
infection by microorganisms, especially Staphylococcus
aureus and Herpes simplex virus. S. aureus can be detect-
ed in 90% of the lesions and it can colonize apparently
healthy skin in AD. This pathogen potentially exacer-
bates or contributes to a persistent inflammation in the
skin of AD patients by secreting toxins with super anti-
genic properties, leading to the activation of T cells and
other immune cells.5,19
Major Criteria
Pruritus
Typical morphology and distribution: adults (flexor surfa-
ces); children and infants (face and extensor surfaces) 
Chronic recidivating dermatitis
Personal or familial history of atopy 
Minor Criteria
Xerosis
Ichthyosis / Keratosis pilaris / Palmar hyperlinearity
Positive cutaneous reactivity
Elevated serum IgE 
Early age of onset
Tendency to skin infections
Dermatitis in hands and feet 
Nipple eczema 
Cheilitis
Conjunctivitis
Dennie-Morgan line
Keratoconus
Anterior subcapsular cataracts
Periorbital darkening
Facial pallor / facial eryhema
Pityriasis alba
Skin folds in the anterior region of the neck 
Sweat-induced pruritus
Intolerance to wool and lipidic solvents
Perifollicular accentuation
Food intolerance
Environmental or emotional factors altering the course of
disease 
White dermographism 
CHART 1: Atopic dermatitis diagnostic criteria
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Local and systemic immune dysregulations
characterize AD. The relationship between the innate
and adaptive immune responses in AD patients
remains to be clarified. The cutaneous inflammation
displays a biphasic pattern of T cell activation. The
predominance of Th2 cytokines in the acute phase of
lesion development (especially IL-4 and IL-13), which
influence the synthesis of IgE and expression of adhe-
sion molecules, is characteristic. The death of S.
aureus by keratinocytes in patients with AD is signif-
icantly inhibited by IL-4 and IL-13. The majority of
AD patients have elevated IgE levels, which are corre-
lated with clinical criteria of disease severity. During
the chronic phase of AD, there is a shift to Th1 pattern,
with production of interferon-gamma.4,5,20,21
The genetic, environmental, immunological and
infectious interactions that lead to an atopic phenotype
expression are not yet fully understood.6 Genomic
studies suggest a probable polygenic inheritance.
There is, however, relatively low concordance of AD
incidence between monozygotic twins, indicating the
multi-causal pathogenesis that influences the risk of
developing a disease and its clinical manifestations. 
It is believed that AD patients carry specific
genes that play an important role together with
“generic” atopy genes.5 In a large cohort study, the risk
of a child having AD was greater when one or both
parents had AD (OR: 3.4, 95% CI 2.6 to 4.4) compared
with the risk when parents had asthma (OR: 1.5, 95%
CI 1.0-2.2) or allergic rhinitis (OR: 1.4, 95% CI 1.1-1.8).22
Studies have identified several genes associated
with AD, but none of them was conclusively identi-
fied as the specific locus or gene. The identified genes
encode proteins involved predominantly in the skin
barrier function, especially filaggrin - as well as the
innate and adaptive immune responses.5
Abnormalities in tight junctions have also been
studied. It has been demonstrated that healthy epithe-
lium, in patients with AD, has bioelectric abnormali-
ties indicative of tight junction defects that may be the
result of decreased levels of claudin-1 (CLDN1), an
adhesion protein.23
VITAMIN D - KNOWLEDGE IN CONSTRUC-
TION
Vitamin D is a liposoluble vitamin synthesized
mainly in the skin. When there is ultraviolet B radia-
tion (UVB) exposure, 7-dehydrocholesterol is convert-
ed to vitamin D3 (cholecalciferol). Vitamin D can also
be obtained through foods and supplements [Vitamin
D2 (ergocalciferol) or D3]. The skin is not able to syn-
thesize vitamin D2.24
Vitamin D increases intestinal calcium absorp-
tion, being thus related to bone metabolism. Its defi-
ciency in children leads to rickets. Additionally, it is
involved in important regulatory mechanisms of the
innate and adaptive immune system.24,25 Current data
demonstrates that vitamin D affects the expression of
more than 200 different genes.
Vitamins D2 and D3 are hydroxylated in the
liver by 25-hydroxylase enzymes, forming 25-hydrox-
yvitamin D or calcidiol [25(OH)D]. In the renal
tubules, 25(OH)D is hydroxylated by 1α-hydroxylase
(CYP27B1) enzymes in 1,25-dihydroxyvitamin D
[1,25(OH)2D], calcitriol, the biologically active form of
vitamin D, that binds to nuclear vitamin D receptor
(VDR) in target tissues. Vitamin D receptors are wide-
ly expressed in more than 30 tissues and organs. The
enzyme 1α-hydroxylase is also expressed in extra-
renal organs, including gastrointestinal tract, skin,
blood vessels, mammary epithelial cells, osteoblasts
and osteoclasts.8
Calcidiol or 25(OH)D is the serum metabolite
that should be measured to determine the overall state
of vitamin D, since it represents a major storage form
of the substance. This circulating form is biologically
inactive; it has a half-life of 2-3 weeks and levels about
1,000 times higher than those of 1,25(OH)2D. More
than 95% of measurable 25(OH)D serum levels corre-
spond to 25(OH)D3.
Calcitriol or 1,25(OH)2D locally produced in tis-
sues such as breast, colon and prostate regulates sev-
eral genes involved in cell proliferation, differentia-
tion, apoptosis and angiogenesis. This explains the
recent association of vitamin D deficiency with an
increased risk of malignancies in those organs.
Calcitriol produced in the kidneys reduces renin pro-
duction and stimulates insulin secretion by pancreatic
β cells.8 Several skin functions are regulated by
1,25(OH)2D and / or its receptor, among which: ker-
atinocytes proliferation inhibition and their differenti-
ation stimulation - including barrier permeability for-
mation – and promotion of innate immunity and hair
follicle’s cycle.26
Vitamin D insufficiency and deficiency repre-
sent a resurgent global health problem. Changes in
lifestyle that have occurred in recent decades, as
reduced sun exposure due to indoor-working, use of
protective clothing and use of sunscreen, largely
explain this vitamin deficiency.27 Insufficient con-
sumption of foods rich in vitamin D and its precursors
is an aggravating factor.28 There are groups at greater
risk of vitamin D non-sufficiency, including women,
African-Americans and individuals with increased
body mass index (BMI) (Chart 2).24,29 The unquestion-
able benefits of using sunscreen are currently con-
fronted by an intense debate that questions the role of
photoprotection in vitamin D deficiency increasingly
found in our times.
Melanin acts as a natural sunscreen and
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decreases the production of vitamin D in human skin.
Individuals with a more pigmented skin require a
longer sun exposure to produce the same amount of
vitamin D compared to those with fair complexions.8
In intertropical zones (between latitudes 23.5°N
and 23.5°S), UVB rays are more intense and vitamin D
synthesis is possible throughout the year. In temper-
ate zones (23.5º- 66.5º), people lack sufficient UVB for
vitamin D synthesis for 1 month during the year,
while those closer to the poles do not get enough UVB
radiation for most of the year.8,30,31 Vitamin D synthesis
is also influenced by the season of the year, with a sea-
sonal decline occurring in winter.32 Studies have
shown a prevalence of vitamin D below 10 mg/ml
ranging from 0 to 32% in adolescents, depending on
latitude and season.33
There were more papers published on vitamin D
in the 21st Century than about any other vitamin,
reflecting the massive expansion of this field of
research. Adequate levels of vitamin D have been asso-
ciated with reduced risk of developing different types
of cancer, bacterial infections, rheumatoid arthritis,
Crohn’s disease, periodontal disease, multiple sclerosis,
asthma, atopic dermatitis, type 1 diabetes, metabolic
syndrome, cardiovascular diseases, stroke, peripheral
artery disease, hypertension, chronic kidney disease,
muscle weakness, cognitive impairment, Alzheimer’s
disease, depression and premature death.28
Despite the numerous studies in progress, there
is no consensus about the optimal serum levels of
vitamin D. Calcidiol levels required for bone health
are generally established by evaluating the level from
which the compensatory elevation of serum parathy-
roid hormone (PTH) begins. This point varied –
depending on the population studied - approximately
between 12 and 30 ng / ml. However, interlaboratory
variations can influence the apparently desired serum
levels of 25(OH)D. The range of values  adopted by
The Endocrine Society are described in chart 3.34,35
Taking into account the physiology of vitamin
D, it could be presumed that the prevalence of its defi-
ciency would be low in sunny countries like Brazil.
However, there is a high prevalence of this hypovita-
minosis even in tropical zones.32 Hypovitaminosis D is
a widespread problem, present in all age groups in
developing countries. It is one of the most prevalent
health problems in childhood, along with infectious
diseases and malnutrition. This hypovitaminosis is
highly prevalent in China, Mongolia, Sub-Saharan
Africa, the Middle East and Latin America, especially
in children, women and the elderly. In China and
Mongolia, it affects more than 50% of children.8
A study conducted in Brazil with 136 adoles-
cents - inhabitants of the countryside of São Paulo (lat-
itude 23ºS) - found vitamin D insufficiency in 60% of
them. The authors suggest that this is predominantly
due to a low vitamin D intake in this group. This find-
ing is disturbing, since the teenage years are critical
for bone mass formation. The same study found that
only 14% of adolescents consume the daily require-
ment of vitamin D and the authors proposed future
actions to implement public policies that stimulate the
addition of vitamin D to food products.32
Also in Brazil, the evaluation of 73 young resi-
dents in a general hospital in Porto Alegre found that
57% had serum levels of 25(OH)D < 20ng/ml.36 In a
cohort of 102 healthy elderly with an average age of 77
years in southern Brazil, 86% also had 25(OH)D below
this value.37
Public health campaigns, as well as supple-
menting foods with vitamin D, are efficient and
affordable actions to prevent vitamin D deficiency.
However, clinical studies are still necessary to evalu-
ate the effect of vitamin D supplementation in classic
and alternative outcomes in developing countries.8
Absence of sun exposure
Skin pigmentation
Type of clothing (veils, scarfs, etc.)
Sunscreen use
Obesity
Newborns, preschoolers, elderly
Institutionalized persons 
Multiple gestations at short intervals
Liver diseases
Malabsorption, short intestine 
Drugs (for instance, rifampicin, glucocorticoids, anticon-
vulsants)
Low socio-economic status
Malnourishment and protein deficiency
Atmospheric pollution
CHART 2: Risk factors for vitamin D deficiency or insufficiency 
Vitamin D status 25(OH)D serum concentration
Deficiency < 20 ng/ml
Insufficiency 20 – 29,9 ng/ml
Normal 30 – 100 ng/ml
CHART 3: Serum reference levels for 25(OH)D 
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ATOPIC DERMATITIS AND VITAMIN D
Among the factors involved in the genesis of AD,
the increasing importance of vitamin D deficiency in
atopic patients may be highlighted. In addition to its
classical role in calcium homeostasis, recent studies
demonstrate the influence of vitamin D in
immunomodulation and cell differentiation, altering the
local balance of calcium and binding to nuclear recep-
tors that regulate gene transcription. It is, furthermore,
associated with keratinocyte production of antimicro-
bial peptides (AMP). Vitamin D and its analogues seem
to play an increasing role in the management of diseases
such as AD, psoriasis, vitiligo, acne and rosacea.17,38-40
RELATIONSHIP BETWEEN SERUM LEVELS OF
VITAMIN D AND THE PREVALENCE / SEVERITY
OF AD 
Few studies have evaluated the prevalence and
severity of AD in vitamin D deficient individuals.
Oren et al. (2008), in a case-control study of 290 obese
patients, observed a 5-fold increase in the likelihood
of AD in subjects with this deficiency when compared
to the group sufficient in vitamin D (p <0.05). There
were no significant associations with asthma or aller-
gic rhinitis.41
Peroni et al. (2011) evaluated the relationship
between vitamin D and AD severity. The study
included 37 children with AD. Serum levels of
25(OH)D were higher in patients with mild AD com-
pared to those with moderate or severe cases (p
<0.05). Data suggest that vitamin D deficiency may be
related to the severity of AD.17
A nutritional survey comparing patients with
AD (n = 132) with healthy controls (n = 132) demon-
strated that patients with AD had a lower vitamin D
dietary intake than the control group. However,
serum vitamin D levels were not measured.42
It has been shown that children born from moth-
ers with low fish or vitamin D intake during pregnan-
cy have an increased prevalence of AD.43,44 In addition,
cross-sectional studies demonstrate a higher preva-
lence of AD in children born during autumn and win-
ter compared with those born in spring and summer.45
Climate and sunlight (ultraviolet radiation)
influence the activity of atopic eczema. Byremo et al.
(2006) randomly selected 30 children from 4-13 years of
age with severe AD in Norway (subarctic / temperate
climate) to settle for 4 weeks in a tropical zone and 26
children to remain in Norway. Patients were followed
for 3 months. A significant reduction in clinical signs
and symptoms as well as an improvement in the qual-
ity of life index was observed in the treated group after
4 weeks and 3 months (p <0.0005). Bacterial coloniza-
tion by S. aureus was reduced in the index group in the
first and third months (p = 0.001 and p = 0.005, respec-
tively). The index group reduced the use of topical cor-
ticosteroids, but not the control group.46 Vitamin D
serum levels were not considered in the study.
Similar associations were found in patients
with psoriasis. Orgaz-Molina et al. (2012) reported a
high prevalence (25.6%) of vitamin D deficiency (<20
ng / ml) in 43 psoriatic patients, regardless of age,
gender and severity of disease. Low levels of 25(OH)D
were negatively associated with markers of inflamma-
tory activity and BMI.47
In a case-control study with 68 psoriatic
patients and 60 controls, the study group had lower
serum levels of 25(OH)D than the healthy subjects (p
<0.05). There was vitamin D deficiency (<20ng/ml) in
68% of the cases, and insufficiency (<30 ng / ml) in
97%. Interestingly, the level of serum 25(OH)D had a
significant negative correlation with the PASI score (p
<0.001), which means a possible direct relationship
between the magnitude of vitamin D deficiency and
disease severity.48
There are, however, many controversies.
Despite the positive association between hypovita-
minosis D and increased prevalence or severity of AD
demonstrated in the aforementioned studies, several
authors have found an inverse association.
Back et al. (2009) showed that the increased
intake of vitamin D during childhood correlates with
an increased risk of AD at 6 years of age. Pre-existing
data on the daily intake of vitamin D3 in the first year
of life were rescued and, through a postal question-
naire the cumulative incidence of AD, allergic rhinitis
or asthma at 6 years of age were investigated in 123
children. AD was more prevalent in the group with
the highest intake of vitamin D3, regardless of family
history of atopy.49 The study sample, however, as the
author points out, was small and more research is
needed to support this association. 
Breastfeeding in the first four months of life
was shown to reduce the risk of childhood eczema at
4 years of age.50 Breastfeeding usually implies in low
intake of vitamin D3, while replacement with infant
formula and dairy drinks with cereal are fortified with
vitamin D3, providing a considerably higher intake.49
Corroborating this association, Milner et al. (2004)
evaluated more than 8,000 patients and demonstrated
that early infant multivitamin supplementation (in the
first 6 months of life) was associated with an increased
risk of food allergies and asthma in black children.51 A
large cohort study in Finland showed that vitamin D
supplementation during the first year of life was asso-
ciated with a higher prevalence of atopy and allergic
rhinitis at 31 years of age.52
However, data on vitamin D dietary intake and
higher prevalence of AD should be taken with cau-
tion, especially regarding the first year of life, a time
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when there is an increased intestinal permeability. The
increase in food sensitization and higher incidence of
atopy in children exposed to foods other than breast
milk is attributed to this increased permeability.
Could there be a significant relationship between the
serum levels of vitamin D and the increased preva-
lence of AD in children with a higher dietary intake of
this substance at an early age? Or is this the result of
an early exposure to various antigens associated with
increased intestinal permeability, a well-known pre-
disposing factor to atopy?
The maternal vitamin D profile during preg-
nancy was also important. Children whose mothers
had increased serum levels of 25(OH)D had a higher
risk of eczema at 9 months and asthma at 9 years old.53
Chiu et al. (2013), in one of the most recent pub-
lished studies on the association between vitamin D
and AD, evaluated 94 children from 1-16 years old liv-
ing in urban Milwaukee (USA). There was no statisti-
cally significant correlation between vitamin D status
and the severity of AD. Interestingly, children with
mild AD had serum levels of 25(OH)D lower than
groups with moderate and severe disease, although
this difference was not statistically significant.54
From the considerations above, we can observe
that this topic is very controversial. Sometimes vitamin
D is considered a protective factor, sometimes a risk
factor for AD. However it seems that there is, at least
quantitatively, a predominance of papers that point to
an inverse association between serum levels of vitamin
D, nutritional intake or sun exposure and the preva-
lence and severity of AD. Not only 25(OH)D but VDR
polymorphism as well has been investigated.
Heine et al. (2013) showed that, in patients with
severe AD, VDR gene polymorphisms are significant-
ly over-represented. The authors investigated the fre-
quency of four of this gene’s most common polymor-
phisms in patients with AD and their potential func-
tional significance. VDR haplotypes were found more
often in patients with severe AD. This finding sug-
gests that VDR contributes to the control of AD and
may have effects on the regulation of epidermal barri-
er function and / or local immune response. VDR can
reduce the expression of proinflammatory cytokines
such as IL -6 and TNF- α in myeloid innate immune
cells and keratinocytes, and inhibit the maturation of
dendritic cells. VDR gene variations may result in
altered responsiveness to vitamin D in inflammatory
conditions. The identified haplotype was previously
associated with asthma in independent cohorts. Since
this haplotype also occurs with high frequency, in
healthy non-atopic individuals, its significance in
severe phenotype cases should be considered more as
that of a cofactor, which requires one or more environ-
mental and / or genetic additional cofactors.55
BIOLOGICAL PLAUSIBILITY: ASSOCIATION
BETWEEN VITAMIN D AND ATOPIC DERMATI-
TIS 
There are several biologically plausible expla-
nations for the inverse relationship between vitamin
D serum levels and the prevalence of AD, in particu-
lar with the severity of this disease.
VITAMIN D: IMMUNE REGULATION AND
ANTIBACTERIAL ACTIVITY
Vitamin D is involved in important regulatory
mechanisms of the innate and adaptive immune system.17
VDR has been found in a variety of cells, including ker-
atinocytes, and numerous cells of the immune system.6
1,25(OH)2D inhibits the proliferation of T cells
(particularly Th1 cells capable of producing interfer-
on-gamma, IL-2 and activating macrophages) and
Th17 cells (capable of producing IL-17 and IL-22).56,57,58
In addition, regulatory CD4 + / CD25 + T cells are
amplified by 1,25(OH)2D, with consequent stimula-
tion of IL-10 production, which further reduces the
development of Th1 and Th17 cells.59,60
Vitamin D affects the production of AMP,
endogenous antibiotics that play a central role in the
pathogenesis of many inflammatory skin diseases
such as AD and psoriasis.25 In vitro studies show that
1,25(OH)2D induces the expression of cathelicidin - a
broad spectrum AMP - in keratinocytes, resulting in
an increased antimicrobial activity against S. aureus
and selective reduction in the expression of cutaneous
lymphocyte -associated antigens.61 A study observed a
significant increase in cathelicidin levels in skin
lesions of 14 patients with moderate to severe AD,
after treatment with 4,000 IU of oral vitamin D for 21
days. The average value went from 3.53 RCU (relative
copy units) to 23.91 RCU after supplementation (p <
0.01). The skin of patients without AD and the healthy
skin of AD patients also showed increased levels of
cathelicidin, although not significant (p> 0.05). These
results suggest that vitamin D oral supplementation
significantly induces the production of cathelicidin in
injured skin of AD patients.62 When monocytes and
macrophages are stimulated by an infectious agent,
there is an increase in the expression of VDR and 1α -
hydroxylase, augmenting the conversion of 25(OH)D
in 1,25(OH)2D and therefore increasing the expression
of cathelicidin.8
Büchau et al. (2009) showed that the low expres-
sion of AMP observed in AD skin samples is associated
with an overexpression of B-cell lymphoma (Bcl)-3
gene. Biopsies of skin lesions showed more Bcl-3 mRNA
than healthy skin biopsies. After vitamin D supplemen-
tation there was less Bcl-3 expression (p = 0.077).63
UVB phototherapy has been successfully used,
for many years, in AD treatment.40 Recent studies sug-
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gest that UVB-induced vitamin D is a possible media-
tor of improvement in the symptoms and severity of
the disease. In a study of patients with AD (n = 18), pso-
riasis (n = 18) and controls (n = 15) exposed to narrow-
band UVB phototherapy, biopsies of lesions in AD
patients showed more AMP than in the control group.64
Matheson et al. (2010) demonstrated that individ-
uals with vitamin D deficiency had a significant
increase in the risk of carrying methicillin-resistant S.
aureus (MRSA).65 It is unclear, however, whether vitamin
D supplementation can reduce MRSA colonization.
VITAMIN D AND THE SKIN BARRIER FUNC-
TION 
Calcitriol [1,25(OH)2D] is known to modulate
the proliferation and differentiation of keratinocytes.5
For this reason, vitamin D3 analogues have been used
to normalize the hyperproliferation present in psoriat-
ic skin.24
In experiments with mice, Hong et al. (2008)
observed a faster recovery of the skin barrier in the
group treated with narrowband UVB phototherapy,
observing higher histological levels of filaggrin and
involucrin in this population. Phototherapy-induced
vitamin D was considered responsible for accelerating
the epidermal barrier recovery.66
Keratinocytes express high levels of 1α-hydrox-
ylase. The product of this enzyme, 1,25(OH)2D pro-
motes in vitro differentiation of keratinocytes. In mice
that lack this enzyme, there is a decrease of involucrin,
filaggrin and loricrin - keratinocyte differentiation
markers - essential for the cornified envelope forma-
tion. Mice that are defective in VDR have an increased
transepidermal water-loss because of the epidermal
barrier breakage. 1,25(OH)2D was found to be essen-
tial for normal epidermal differentiation, probably by
inducing proteins and mediating calcium signaling in
the epidermis, steps that are necessary for the genera-
tion and maintenance of the skin barrier.67
Studies on psoriasis indicate that the topical
treatment with calcipotriol, 1,25(OH)2D analog,
increases VDR expression in keratinocytes. Effects of
calcipotriol in epidermal keratinocytes proliferation
and differentiation were more pronounced than its
effects on dermic inflammation.68
Russel (2012) evaluated the association between
25(OH)D serum levels and stratum corneum conduc-
tance in 83 female patients from 18 to 45 years old. The
author found smaller amounts of vitamin D in patients
with lower levels of skin hydration (p = 0.02).24
Observations that topical calcineurin inhibitors
may partially correct the barrier defect in AD and that
gentamicin can restore the production of filaggrin
chains provide additional evidence of the complex rela-
tion between epidermal barrier and immune system.69
THERAPEUTIC ROLE OF VITAMIN D SUPPLE-
MENTATION IN ATOPIC DERMATITIS
Confirming the data obtained from observation-
al studies, recent clinical trials suggest a therapeutic role
for vitamin D supplementation in the treatment of AD.40
Sidbury et al. (2008) conducted a randomized
double-blind study in which 11 children aged 2-13
years received 1,000 IU of vitamin D or placebo dur-
ing one month. Four of the five children who received
vitamin D showed improvement, while only one of
the six children in the control group improved (p =
0.04).70 The small number of participants limits the
power of the study. 
Amestejani et al. (2012) published a
randomized, double-blind, placebo-controlled trial in
which 30 patients received vitamin D 1,600 IU / day
and 30 patients received placebo. After 60 days, the
group treated with vitamin D improved significantly,
regardless of the initial severity of AD (p <0.05). In the
placebo group, the improvement was not significant
(p> 0.05). Serum levels of 25(OH)D in the treatment
group were significantly higher than baseline values
(p = 0.001). The study results suggest that vitamin D
supplementation improves AD.6
Another study evaluated the effects of vitamins
D and E supplementation in clinical manifestations of
AD. Forty-five patients with AD were included in a
randomized, double blind, placebo-controlled study.
Clinical improvement was evaluated using SCORAD,
which showed significant reduction after 60 days in
the groups receiving vitamin D or E, or both vitamins
(p = 0.004).71
CONCLUSIONS
Hypovitaminosis D has emerged as a potential
risk factor for infections, allergic disorders and chron-
ic diseases. The possible consequences of hypovita-
minosis D high prevalence are worrisome, given the
recognition of various non-skeletal physiological
actions of vitamin D. The need for public healthcare
advertising campaigns warning about the importance
of vitamin D is pressing, especially in countries where
there is a high prevalence of hypovitaminosis.
It is necessary to explain with due emphasis to
the population, the harmful effects of unprotected
sunlight exposure and the actual impact of sunscreen
use in vitamin D production, since it is common that
non-dermatologists suggest this practice, which
could, in the future, reduce the prevalence of hypovi-
taminosis D and, conversely, increase the incidence of
cutaneous neoplasms.
There are several limitations in vitamin D stud-
ies, such as the lack of standardization for its serum
level’s measurement, a wide range of reference values
used to define deficiency and insufficiency and hap-
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hazard measurements of vitamin D in a given period,
which may not reflect the real status of the patient.8
The role of vitamin D and its metabolites in pre
and postnatal maturation of lymphoid and epithelial
tissues, involved in the development of cutaneous and
respiratory allergic manifestations, remains controver-
sial suggesting both strengthening and protecting
mechanisms.6 Further studies are needed to clarify this
discussion. Any conclusion would still be premature.
There are encouraging results regarding the
therapeutic use of adjuvant vitamin D in AD. They
must, meanwhile, be regarded with caution.
Randomized controlled trials adequately designed in
order to establish optimal dose, duration and effect of
vitamin D supplementation in various health out-
comes are still needed. In the field of AD, future stud-
ies should investigate the optimal levels of vitamin D
necessary to maintain cutaneous health and their cor-
relation to serum levels, as well as clarify the role of
vitamin D in dry skin.
Vitamin D can be on the opposite side of several
known AD associations, such as the protection afford-
ed by breastfeeding, low bone mineral density in
patients with AD, clinical improvement after sun expo-
sure and the benefits provided by phototherapy.50,46,72,73
Vitamin D decreases the susceptibility to infec-
tion in patients with AD and controls the local inflam-
matory immune response, representing a promising
tool for the understanding and treatment of this
chronic inflammatory disease.7 q
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